Noninvasive model including right ventricular speckle tracking for the evaluation of pulmonary hypertension

Table 2 Baseline characteristics

	All patients (n = 44)	No PH (n = 10)	Precapillary PH (n = 15)	Postcapillary PH (n = 19)	P
Age, yr	63.11 ± 14.2	60.3 ± 16.9	60.2 ± 13	66.9 ± 13.3	0.71
Male gender, n (%)	27 (61)	5 (50)	8 (53)	14 (74)	0.33
AHT, n (%)	30 (60)	8 (61)	7 (53)	15 (62)	0.82
Diabetes mellitus, n (%)	11 (22)	2 (15)	3 (23)	6 (25)	0.57
CAD, n (%)	26 (52)	7 (53)	7 (53)	12 (50)	0.44
HLP, n (%)	15 (30)	4 (31)	6 (25)	5 (38)	0.33
Nicotine, n (%)	10 (20)	3 (23)	5 (21)	2 (15)
Specific PAH Therapy, n (%)	15 (34)	0 (0)	15 (100)	0 (0)	< 0.001
ECG RV strain, n (%)	26 (59)	2 (20)	13 (87)	11 (58)	0.001
NT pro-BNP (pg/mL)	2778.3 ± 5681.3	367.5 ± 420.4	1980.3 ± 3432.1	4677 ± 7764.8	0.44
Hemoglobine, mg/dL	12.8 ± 3.6	11.4 ± 0.9	12.2 ± 2.5	12.6 ± 3.4	0.09
Bilirubin, mg/dL	0.7 ± 0.5	0.5 ± 0.2	0.9 ± 0.8	0.8 ± 0.3	0.08
Uric acid, mg/dL	7.1 ± 2.6	6.0 ± 1.7	6.9 ± 2.6	7.9 ± 2.8	0.13
Serum creatinine, mg/dL	1.3 ± 0.3	1.0 ± 0.2	1.3 ± 0.4	1.2 ± 0.2	0.25
Creatinine clearance, mL/min	55.3 ± 13.4	53.2 ± 8.9	50.5 ± 11.4	57.2 ± 6.3	0.48
6MWD, m	351.9 ± 153.2	372.5 ± 127.5	375.3 ± 186.8	319.5 ± 131.9	0.55

AHT: Arterial hypertension; CAD: Coronary artery disease; HLP: Hyperlipoproteinemia; PAH: Pulmonary arterial hypertension; ECG: Electrocardiogram; RV: Right ventricular; NT pro-BNP: N-terminal pro brain-natriuretic-peptide; 6MWD: 6 min walking distance.